Stay updated on PEOPLE: Pembrolizumab in Low PD-L1 NSCLC Clinical Trial
Sign up to get notified when there's something new on the PEOPLE: Pembrolizumab in Low PD-L1 NSCLC Clinical Trial page.

Latest updates to the PEOPLE: Pembrolizumab in Low PD-L1 NSCLC Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.0%
- Check18 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference0.5%
- Check25 days agoChange DetectedThe page has undergone significant changes with the removal of several key research articles and their corresponding citations, which may impact the credibility and comprehensiveness of the content related to cancer research.SummaryDifference0.7%
- Check32 days agoChange DetectedThe page has removed a citation regarding a study on tumor-associated B7-H1 and its role in T-cell apoptosis, including an erratum reference.SummaryDifference0.1%
- Check39 days agoChange DetectedThe page has removed a citation regarding improved survival with ipilimumab in patients with metastatic melanoma, which is a significant change in core content.SummaryDifference0.1%
- Check46 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.0%
Stay in the know with updates to PEOPLE: Pembrolizumab in Low PD-L1 NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PEOPLE: Pembrolizumab in Low PD-L1 NSCLC Clinical Trial page.